Mechanism of immune dysfunction in sepsis: Inducible nitric oxide-meditated alterations in p38 MAPK activation

Journal of Trauma

Volumn 53, Issue 2, 2002, Pages 276-283

  Song, Grace Y ^a   Chung, Chun Shiang ^a   Jarrar, Doraid ^a   Cioffi, William G ^a   Ayala, Alfred ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Cecal ligation and puncture (CLP); Immune suppression; iNOS knockout; Mouse; Nitric oxide; p38 MAPK; Sepsis

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY CD3; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CELLULAR IMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; IMMUNE SYSTEM; IMMUNOBLOTTING; KNOCKOUT MOUSE; MACROPHAGE; MALE; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SEPSIS; T LYMPHOCYTE;

ANIMALS; CYTOKINES; IMMUNITY, CELLULAR; MALE; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASES; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SEPSIS; STATISTICS, NONPARAMETRIC;

EID: 0036686075     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005373-200208000-00015     Document Type: Article

References (46)

1. Mannick JA. Trauma, sepsis and immune defects. In; Faist E, Meakins JL, Schildberg FW, eds. Host Defense Dysfunction in Trauma, Shock and Sepsis. Berlin; Springer-Verlag; 1993; 15-21.
2. Baue AE. Multiple Organ Failure; Patient Care and Prevention. St Louis; Mosby; 1990; 336-363.
3. Song GY, Chung CS, Chaudry IH, Ayala A. What is IL-10's role in polymicrobial sepsis; anti-inflammatory agent or immune suppressant? Surgery. 1999; 126; 378-383.
4. Ayala A, Deol ZK, Lehman DL, Herdon CD, Chaudry IH. Polymicrobial sepsis but not low dose endotoxin infusion causes decreased splenocyte IL-2/IFN-gamma release while increasing IL-4/IL-10 production. J Surg Res. 1994; 56; 579-585.
5. O'Sullivan ST, Lederer JA, Horgan AF, Chin DHL, Mannick JA, Rodrick ML. Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. Ann Surg. 1995; 222; 482-492.
6. DiPiro JT, Howdieshell TR, Goddard JK, Callaywa DB, Hamilton RG, Mansberger AR. Association of interleukin-4 plasma levels with traumatic injury and clinical course. Arch Surg. 1998; 130; 1159-1163.
7. Langrehr JM, Hoffman RA, Lancaster JR Jr, Simmons RL. Nitric oxide; a new endogenous immunomodulator. Transplantation. 1993; 55; 1205-1212.
8. Nussler AK, Di Silvio M, Billiar TR, et al. Stimulation of the nitric oxide synthase pathway in human hepatocytes by cytokines and endotoxin. J Exp Med. 1992; 176; 261-264.
9. Lejeune P, Lagadec P, Onier N, Pinnard D, Ohshima H, Jeannin JF. Nitric oxide involvement in tumor-induced immunosuppression. J Immunol. 1994; 152; 5077-5083.
10. Sicher SC, Vazquez MA, Lu CY. Inhibition of macrophage Ia expression by nitric oxide. J Immunol. 1994; 153; 1293-1300.
11. Napolitano LM, Campbell C. Nitric oxide inhibition normalizes splenocyte interleukin-10 synthesis in murine thermal injury. Arch Surg. 1994; 129; 1276-1282.
12. Fecho K, Maslonek KA, Coussons-Read ME, Dykstra LA, Lysle DT. Macrophage-derived nitric oxide is involved in the depressed concanavalin A responsiveness of splenic lymphocytes from rats administered morphine in vivo. J Immunol. 1994; 152; 5845-5852.
13. Cobb JP, Buchman TG, Chang K, Qui Y, Laubach VE, Hotchkiss RS. iNOS gene deficiency increases the mortality of sepsis in mice. Surgery. 1999; 126; 432-439.
14. Laubach VE, Shesely EG, Smithies O, Sherman PA. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc Natl Acad Sci USA. 1995; 92; 10688-10692.
15. Hollenberg SM, Broussard M, Osman J, Parrillo JE. Increased microvascular reactivity and improved mortality in septic mice lacking inducible nitric oxide synthase. Circ Res. 2000; 86; 774-778.
16. Chung CS, Song GY, Wang W, Chaudry IH, Ayala A. Septic mucosal intraepithelial lymphoid immune suppression; role for nitric oxide not interleukin-10 or transforming growth factor-&bgr;. J Trauma. 2000; 48; 807-813.
17. Lee JC, Young PR. Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. J Leukoc Biol. 1996; 59; 152-157.
18. Han J, Jiang Y, Li Z, Kravchenko VV, Ulevitch RJ. Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature. 1997; 386; 296-299.
19. Schafer PH, Wadsworth SA, Wang L, Siekierka JJ. p38alpha mitogen-activated protein kinase is activated by CD28-mediated signaling and is required for IL-4 production by human CD4+CD45RO+ T cells and Th2 effector cells. J Immunol. 1999; 162; 7110-7119.
20. Koprak S, Staruch MJ, Dumont FJ. A specific inhibitor of the p38 mitogen activated protein kinase affects differentially the production of various cytokines by activated human T cells; dependence on CD28 signaling and preferential inhibition of IL-10 production. Cell Immunol. 1999; 192; 87-85.
21. Rincon M, Enslen H, Raingeaud J, et al. Interferon-gamma expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. EMBO J. 1998; 17; 2817-2829.
22. Sugawara T, Moriguchi T, Nishida E, Takahama Y. Differential roles of ERK and p38 MAP kinase pathways in positive and negative selection of T lymphocytes. Immunity. 1998; 9; 565-574.
23. Marshall LA, Hansbury MJ, Bolognese BJ, Gum RJ, Young PR, Mayer RJ. Inhibitors of the p38 mitogen-activated kinase modulate IL-4 induction of low affinity IgE receptor (CD23) in human monocytes. J Immunol. 1999; 161; 6005-6013.
24. Song GY, Chung CS, Jarrar D, Chaudry IH, Ayala A. Evolution of an immune suppressive macrophage phenotype as a product of p38 MAPK activation in polymicrobial sepsis. Shock. 2001; 15; 42-48.
25. Caiviano M. Role of MAP kinase cascades in inducing arginine transporters and nitric oxide synthetase in RAW264 macrophages. FEBS Lett. 1998; 429; 249-253.
26. Ajizian SJ, English BK, Meals EA. Specific inhibitors of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways block inducible nitric oxide synthase and tumor necrosis factor accumulation in murine macrophages stimulated with lipopolysaccharide and interferon-gamma. J Infect Dis. 1999; 179; 939-944.
27. Ingram AJ, James L, Thai K, Ly H, Cai L, Scholey JW. Nitric oxide modulates mechanical strain-induced activation of p38 MAPK in mesangial cells. Am J Physiol. 2000; 279; F243-F251.
28. Baker CC, Chaudry IH, Gaines HO, Baue AE. Evaluation of factors affecting mortality rate after sepsis in murine cecal ligation and puncture model. Surgery. 1983; 94; 331-335.
29. Ayala A, Perrin MM, Kisala JM, Ertel W, Chaudry IH. Polymicrobial sepsis selectively activates peritoneal but not alveolar macrophage to release inflammatory mediators (IL-1, IL-6 and TNF). Circ Shock. 1992; 36; 191-199.
30. Meldrum DR, Ayala A, Perrin MM, Ertel W, Chaudry IH. Diltiazem restores IL-2, IL-3, IL-6 and IFN-gamma synthesis and decreases susceptibility to sepsis following hemorrhage. J Surg Res. 1991; 51; 158-164.
31. Song GY, Chung CS, Schwacha MG, Jarrar D, Chaudry IH, Ayala A. Splenic immune suppression in sepsis; a role for IL-10 induced changes in P38 MAPK signaling. J Surg Res. 1999; 83; 36-43.
32. Zedler S, Bone RC, Baue AE, von Donnersmarck GH, Faist E. T-cell reactivity and its predictive role in immunosuppression after burns. Crit Care Med. 1999; 27; 66-72.
33. Heidecke CD, Hensler T, Weighardt H, et al. Selective defects of T lymphocyte function in patients with lethal intraabdominal infection. Am J Surg. 1999; 178; 288-292.
34. Ayala A, Knotts JB, Ertel W, Perrin MM, Morrison MH, Chaudry IH. Role of interleukin 6 and transforming growth factor-beta in the induction of depressed splenocyte responses following sepsis. Arch Surg. 1993; 128; 89-95.
35. Mosmann TR, Coffman RL. TH1 and TH2 cells; different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol. 1989; 7; 145-173.
36. Ferguson NR, Galley HF, Webster NR. T helper subset ratios in patients with severe sepsis. Intensive Care Med. 1999; 1; 106-109.
37. Hierholzer C, Harbrecht B, Menezes JM, et al. Essential role of induced nitric oxide in the initiation of the inflammatory response after hemorrhagic shock. J Exp Med. 1998; 187; 917-928.
38. Ingram AJ, James L, Cai L, Thai K, Ly H, Scholey JW. NO inhibits stretch-induced MAPK activity by cytoskeletal disruption. J Biol Chem. 2000; 275; 40301-40306.
39. Evans T, Carpenter A, Kinderman H, Cohen J. Evidence of increased nitric oxide production in patients with the sepsis syndrome. Circ Shock. 1993; 41; 77-81.
40. Ochoa JB, Udekwu AO, Billiar TB, et al. Nitrogen oxide levels in patients after trauma and during sepsis. Ann Surg. 1991; 214; 621-626.
41. Gomez-Jimenez J, Salgado A, Mourelle M, et al. L-arginine; nitric oxide pathway in endotoxemia and human septic shock. Crit Care Med. 1995; 23; 253-258.
42. Hollenberg SM, Broussard M, Osman J, Parrillo JE. Increased microvascular reactivity and improved mortality in septic mice lacking inducible nitric oxide synthase. Circ Res. 2000; 86; 774-778.
43. Deora AA, Hajjar DP, Lander HM. Recruitment and activation of Raf-1 kinase by nitric oxide-activated Ras. Biochemistry. 2000; 39; 9901-9908.
44. Browning DD, Windes ND, Ye RD. Activation of p38 mitogen-activated protein kinase by lipopolysaccharide in human neutrophils requires nitric oxide-dependent cGMP accumulation. J Biol Chem. 1999; 274; 537-542.
45. Yuasa T, Ohno S, Kehrl JH, Kyriakis JM. TNF signaling to stress-activated protein kinases (SAPK)/jun-NH2-terminal kinase (JNK)and p38. J Biol Chem. 1998; 273; 22681-22692.
46. Kanakaraj P, Schafer PH, Cavender DE, et al. IL-1 receptor-associated kinase (IRAK) requirement for optimal induction of multiple IL-1 signaling pathways and IL-6 production. J Exp Med. 1998; 187; 2073-2079.